Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials.

Khan A, Faucett J, Morrison S, Brown WA.

JAMA Psychiatry. 2013 Oct;70(10):1091-9. doi: 10.1001/jamapsychiatry.2013.149.

PMID:
23986353
[PubMed - indexed for MEDLINE]
2.

Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.

Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson DS.

J Clin Psychiatry. 2007 Dec;68(12):1828-33.

PMID:
18162012
[PubMed - indexed for MEDLINE]
3.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
[PubMed - indexed for MEDLINE]
Free Article
4.

Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.

Alper K, Schwartz KA, Kolts RL, Khan A.

Biol Psychiatry. 2007 Aug 15;62(4):345-54. Epub 2007 Jan 16.

PMID:
17223086
[PubMed - indexed for MEDLINE]
5.

Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports.

Khan A, Schwartz K, Redding N, Kolts RL, Brown WA.

Neuropsychopharmacology. 2007 Nov;32(11):2422-30. Epub 2007 Feb 21.

PMID:
17314915
[PubMed - indexed for MEDLINE]
Free Article
6.

Suicidality in pediatric patients treated with antidepressant drugs.

Hammad TA, Laughren T, Racoosin J.

Arch Gen Psychiatry. 2006 Mar;63(3):332-9.

PMID:
16520440
[PubMed - indexed for MEDLINE]
7.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
[PubMed - indexed for MEDLINE]
8.

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S.

Portland (OR): Oregon Health & Science University; 2010 Jul.

PMID:
21348048
[PubMed]
Books & Documents
9.

[Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].

Hjalmarsson L, Corcos M, Jeammet P.

Encephale. 2005 May-Jun;31(3):309-16. French.

PMID:
16142045
[PubMed - indexed for MEDLINE]
10.

Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.

Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D, Bond GR, Huxley P, Tyrer P.

Health Technol Assess. 2001;5(21):1-75. Review.

PMID:
11532238
[PubMed - indexed for MEDLINE]
Free Article
11.

Suicide rates in short-term randomized controlled trials of newer antidepressants.

Hammad TA, Laughren TP, Racoosin JA.

J Clin Psychopharmacol. 2006 Apr;26(2):203-7.

PMID:
16633153
[PubMed - indexed for MEDLINE]
12.

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.

Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA.

JAMA. 2007 Apr 18;297(15):1683-96.

PMID:
17440145
[PubMed - indexed for MEDLINE]
13.

Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Loy JH, Merry SN, Hetrick SE, Stasiak K.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD008559. doi: 10.1002/14651858.CD008559.pub2. Review.

PMID:
22972123
[PubMed - indexed for MEDLINE]
14.

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.

Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23. Review.

PMID:
18501566
[PubMed - indexed for MEDLINE]
15.

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14. Review.

PMID:
19840150
[PubMed - indexed for MEDLINE]
16.

Magnitude of placebo response and drug-placebo differences across psychiatric disorders.

Khan A, Kolts RL, Rapaport MH, Krishnan KR, Brodhead AE, Browns WA.

Psychol Med. 2005 May;35(5):743-9.

PMID:
15918351
[PubMed - indexed for MEDLINE]
17.
18.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

PMID:
14994733
[PubMed - indexed for MEDLINE]
19.

Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.

Khan A, Khan S, Kolts R, Brown WA.

Am J Psychiatry. 2003 Apr;160(4):790-2.

PMID:
12668373
[PubMed - indexed for MEDLINE]
20.

Newer generation antidepressants for depressive disorders in children and adolescents.

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851. doi: 10.1002/14651858.CD004851.pub3. Review.

PMID:
23152227
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk